Pharmaceutical markets and insurance worldwide:
Gespeichert in:
| Format: | Elektronisch E-Book |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Bingley, UK
Emerald/JAI
2010
|
| Ausgabe: | 1st ed |
| Schriftenreihe: | Advances in health economics and health services research
v. 22 |
| Schlagworte: | |
| Online-Zugang: | FAW01 FAW02 FLA01 Volltext |
| Beschreibung: | Includes bibliographical references Part I: International reviews -- - Pharmaceutical policies in European countries - Pedro Pita Barros -- - International experience with comparative effectiveness research : case studies from England/Wales and Germany - John F.P. Bridges ... [et al.] -- - Part II: National case studies -- - Pharmaceutical policy in the Netherlands : from price regulation towards managed competition - Lieke H.H.M. Boonen ... [et al.] -- - Impact of pharmaceutical regulation and policies on health system performance goals in israel - Philip Sax and Amir Shmueli -- - Global budgets and provider incentives : hospitals' drug expenditures in Taiwan - Shin-Yi Chou ... [et al.] -- - Medicare Part D turns four : trends in plan design, enrollment, and the impact of the program on beneficiaries - Jack Hoadley and Kosali Simon -- - Part III: U.S. studies : from markets to policy innovations -- - Does prescription drug adherence reduce hospitalizations and costs? The case of diabetes - William E. Encinosa, Didem Bernard and Avi Dor -- - Cost shring, benefit design, and adherence : the case of multiple sclerosis - Avi Dor ... [et al.] -- - Generic utilization and cost-sharing for prescription drugs - Teresa Bernard Gibson, Catherine G. McLaughlin and Dean G. Smith -- - Drug prices, out-of-pocket payments, and insurer costs : how do payers vary? - Jie Chen and John A. Rizzo -- - Adverse selection and the effect of health insurance on utilization of prescribed medicine among patients with chronic conditions - Yuriy Pylypchuk -- - The effect of drug vintage on survival : micro evidence from Puerto Rico's Medicaid program - Frank R. Lichtenberg -- - Part IV: Special topics -- - Retail pharmacy market structure and insurer-independent pharmacy bargaining in the Medicare Part D era - Yang Xie ... [et al.] -- - Patents, innovation, and the welfare effects of Medicare Part D - Adam Gailey, Darius Lakdawalla and Neeraj Sood The fields of pharmaceutical economics and health economics/policy are reaching a point of convergence. This is due to both the widespread availability of pharmaceutical treatments, accompanied by broader insurance coverage, and the regulation of prescription drugs in both private and government plans. This book will bridge the gap. We will explore developments in both U.S. and International setting. The system of the U.S. is characterized by a mix of private and government insurance for prescription drugs with the expansion of Medicare Part D. Most other developed countries are characterized by social insurance with either the government as a single payer such as in Canada or Australia, or a national health service as in many other European countries |
| Beschreibung: | 1 Online-Ressource (xxi, 344 p.) |
| ISBN: | 1849507171 9781849507172 |
Internformat
MARC
| LEADER | 00000nmm a2200000zcb4500 | ||
|---|---|---|---|
| 001 | BV043116375 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 151126s2010 |||| o||u| ||||||eng d | ||
| 020 | |a 1849507171 |c electronic bk. |9 1-84950-717-1 | ||
| 020 | |a 9781849507172 |c electronic bk. |9 978-1-84950-717-2 | ||
| 035 | |a (OCoLC)649478955 | ||
| 035 | |a (DE-599)BVBBV043116375 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-1046 |a DE-1047 |a DE-860 | ||
| 082 | 0 | |a 338.47615 |2 22 | |
| 245 | 1 | 0 | |a Pharmaceutical markets and insurance worldwide |c edited by Avi Dor |
| 250 | |a 1st ed | ||
| 264 | 1 | |a Bingley, UK |b Emerald/JAI |c 2010 | |
| 300 | |a 1 Online-Ressource (xxi, 344 p.) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Advances in health economics and health services research |v v. 22 | |
| 500 | |a Includes bibliographical references | ||
| 500 | |a Part I: International reviews -- - Pharmaceutical policies in European countries - Pedro Pita Barros -- - International experience with comparative effectiveness research : case studies from England/Wales and Germany - John F.P. Bridges ... [et al.] -- - Part II: National case studies -- - Pharmaceutical policy in the Netherlands : from price regulation towards managed competition - Lieke H.H.M. Boonen ... [et al.] -- - Impact of pharmaceutical regulation and policies on health system performance goals in israel - Philip Sax and Amir Shmueli -- - Global budgets and provider incentives : hospitals' drug expenditures in Taiwan - Shin-Yi Chou ... [et al.] -- - Medicare Part D turns four : trends in plan design, enrollment, and the impact of the program on beneficiaries - Jack Hoadley and Kosali Simon -- - Part III: U.S. studies : from markets to policy innovations -- - Does prescription drug adherence reduce hospitalizations and costs? The case of diabetes - William E. Encinosa, Didem Bernard and Avi Dor -- - Cost shring, benefit design, and adherence : the case of multiple sclerosis - Avi Dor ... [et al.] -- - Generic utilization and cost-sharing for prescription drugs - Teresa Bernard Gibson, Catherine G. McLaughlin and Dean G. Smith -- - Drug prices, out-of-pocket payments, and insurer costs : how do payers vary? - Jie Chen and John A. Rizzo -- - Adverse selection and the effect of health insurance on utilization of prescribed medicine among patients with chronic conditions - Yuriy Pylypchuk -- - The effect of drug vintage on survival : micro evidence from Puerto Rico's Medicaid program - Frank R. Lichtenberg -- - Part IV: Special topics -- - Retail pharmacy market structure and insurer-independent pharmacy bargaining in the Medicare Part D era - Yang Xie ... [et al.] -- - Patents, innovation, and the welfare effects of Medicare Part D - Adam Gailey, Darius Lakdawalla and Neeraj Sood | ||
| 500 | |a The fields of pharmaceutical economics and health economics/policy are reaching a point of convergence. This is due to both the widespread availability of pharmaceutical treatments, accompanied by broader insurance coverage, and the regulation of prescription drugs in both private and government plans. This book will bridge the gap. We will explore developments in both U.S. and International setting. The system of the U.S. is characterized by a mix of private and government insurance for prescription drugs with the expansion of Medicare Part D. Most other developed countries are characterized by social insurance with either the government as a single payer such as in Canada or Australia, or a national health service as in many other European countries | ||
| 650 | 7 | |a BUSINESS & ECONOMICS / Industries / Service |2 bisacsh | |
| 650 | 7 | |a Health insurance / Costs |2 fast | |
| 650 | 7 | |a Health insurance / Finance |2 fast | |
| 650 | 7 | |a Medical economics |2 fast | |
| 650 | 7 | |a Pharmaceutical industry / Economic aspects |2 fast | |
| 650 | 4 | |a Drug Industry / economics | |
| 650 | 4 | |a Economics, Medical | |
| 650 | 4 | |a Insurance, Health / economics | |
| 650 | 7 | |a Gestion d'entreprises |2 eclas | |
| 650 | 4 | |a Industrie | |
| 650 | 4 | |a Wirtschaft | |
| 650 | 4 | |a Pharmaceutical industry |x Economic aspects | |
| 650 | 4 | |a Medical economics | |
| 650 | 4 | |a Health insurance |x Finance | |
| 650 | 4 | |a Health insurance |x Costs | |
| 700 | 1 | |a Dor, Avi |e Sonstige |4 oth | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe, Hardcover |z 1-84950-716-3 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe, Hardcover |z 978-1-84950-716-5 |
| 856 | 4 | 0 | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=318261 |x Aggregator |3 Volltext |
| 912 | |a ZDB-4-EBA | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-028540566 | ||
| 966 | e | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=318261 |l FAW01 |p ZDB-4-EBA |q FAW_PDA_EBA |x Aggregator |3 Volltext | |
| 966 | e | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=318261 |l FAW02 |p ZDB-4-EBA |q FAW_PDA_EBA |x Aggregator |3 Volltext | |
| 966 | e | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=318261 |l FLA01 |p ZDB-4-EBA |q FLA_PDA_EBU |x Aggregator |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804175541396307968 |
|---|---|
| any_adam_object | |
| building | Verbundindex |
| bvnumber | BV043116375 |
| collection | ZDB-4-EBA |
| ctrlnum | (OCoLC)649478955 (DE-599)BVBBV043116375 |
| dewey-full | 338.47615 |
| dewey-hundreds | 300 - Social sciences |
| dewey-ones | 338 - Production |
| dewey-raw | 338.47615 |
| dewey-search | 338.47615 |
| dewey-sort | 3338.47615 |
| dewey-tens | 330 - Economics |
| discipline | Wirtschaftswissenschaften |
| edition | 1st ed |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>05179nmm a2200601zcb4500</leader><controlfield tag="001">BV043116375</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">151126s2010 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1849507171</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">1-84950-717-1</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781849507172</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">978-1-84950-717-2</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)649478955</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV043116375</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-1046</subfield><subfield code="a">DE-1047</subfield><subfield code="a">DE-860</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">338.47615</subfield><subfield code="2">22</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pharmaceutical markets and insurance worldwide</subfield><subfield code="c">edited by Avi Dor</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">1st ed</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Bingley, UK</subfield><subfield code="b">Emerald/JAI</subfield><subfield code="c">2010</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (xxi, 344 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Advances in health economics and health services research</subfield><subfield code="v">v. 22</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Part I: International reviews -- - Pharmaceutical policies in European countries - Pedro Pita Barros -- - International experience with comparative effectiveness research : case studies from England/Wales and Germany - John F.P. Bridges ... [et al.] -- - Part II: National case studies -- - Pharmaceutical policy in the Netherlands : from price regulation towards managed competition - Lieke H.H.M. Boonen ... [et al.] -- - Impact of pharmaceutical regulation and policies on health system performance goals in israel - Philip Sax and Amir Shmueli -- - Global budgets and provider incentives : hospitals' drug expenditures in Taiwan - Shin-Yi Chou ... [et al.] -- - Medicare Part D turns four : trends in plan design, enrollment, and the impact of the program on beneficiaries - Jack Hoadley and Kosali Simon -- - Part III: U.S. studies : from markets to policy innovations -- - Does prescription drug adherence reduce hospitalizations and costs? The case of diabetes - William E. Encinosa, Didem Bernard and Avi Dor -- - Cost shring, benefit design, and adherence : the case of multiple sclerosis - Avi Dor ... [et al.] -- - Generic utilization and cost-sharing for prescription drugs - Teresa Bernard Gibson, Catherine G. McLaughlin and Dean G. Smith -- - Drug prices, out-of-pocket payments, and insurer costs : how do payers vary? - Jie Chen and John A. Rizzo -- - Adverse selection and the effect of health insurance on utilization of prescribed medicine among patients with chronic conditions - Yuriy Pylypchuk -- - The effect of drug vintage on survival : micro evidence from Puerto Rico's Medicaid program - Frank R. Lichtenberg -- - Part IV: Special topics -- - Retail pharmacy market structure and insurer-independent pharmacy bargaining in the Medicare Part D era - Yang Xie ... [et al.] -- - Patents, innovation, and the welfare effects of Medicare Part D - Adam Gailey, Darius Lakdawalla and Neeraj Sood</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">The fields of pharmaceutical economics and health economics/policy are reaching a point of convergence. This is due to both the widespread availability of pharmaceutical treatments, accompanied by broader insurance coverage, and the regulation of prescription drugs in both private and government plans. This book will bridge the gap. We will explore developments in both U.S. and International setting. The system of the U.S. is characterized by a mix of private and government insurance for prescription drugs with the expansion of Medicare Part D. Most other developed countries are characterized by social insurance with either the government as a single payer such as in Canada or Australia, or a national health service as in many other European countries</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">BUSINESS & ECONOMICS / Industries / Service</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Health insurance / Costs</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Health insurance / Finance</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Medical economics</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pharmaceutical industry / Economic aspects</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Industry / economics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Economics, Medical</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Insurance, Health / economics</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Gestion d'entreprises</subfield><subfield code="2">eclas</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Industrie</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Wirtschaft</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmaceutical industry</subfield><subfield code="x">Economic aspects</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medical economics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Health insurance</subfield><subfield code="x">Finance</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Health insurance</subfield><subfield code="x">Costs</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dor, Avi</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe, Hardcover</subfield><subfield code="z">1-84950-716-3</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe, Hardcover</subfield><subfield code="z">978-1-84950-716-5</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=318261</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-028540566</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=318261</subfield><subfield code="l">FAW01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FAW_PDA_EBA</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=318261</subfield><subfield code="l">FAW02</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FAW_PDA_EBA</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=318261</subfield><subfield code="l">FLA01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FLA_PDA_EBU</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV043116375 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T07:17:56Z |
| institution | BVB |
| isbn | 1849507171 9781849507172 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-028540566 |
| oclc_num | 649478955 |
| open_access_boolean | |
| owner | DE-1046 DE-1047 DE-860 |
| owner_facet | DE-1046 DE-1047 DE-860 |
| physical | 1 Online-Ressource (xxi, 344 p.) |
| psigel | ZDB-4-EBA ZDB-4-EBA FAW_PDA_EBA ZDB-4-EBA FLA_PDA_EBU |
| publishDate | 2010 |
| publishDateSearch | 2010 |
| publishDateSort | 2010 |
| publisher | Emerald/JAI |
| record_format | marc |
| series2 | Advances in health economics and health services research |
| spelling | Pharmaceutical markets and insurance worldwide edited by Avi Dor 1st ed Bingley, UK Emerald/JAI 2010 1 Online-Ressource (xxi, 344 p.) txt rdacontent c rdamedia cr rdacarrier Advances in health economics and health services research v. 22 Includes bibliographical references Part I: International reviews -- - Pharmaceutical policies in European countries - Pedro Pita Barros -- - International experience with comparative effectiveness research : case studies from England/Wales and Germany - John F.P. Bridges ... [et al.] -- - Part II: National case studies -- - Pharmaceutical policy in the Netherlands : from price regulation towards managed competition - Lieke H.H.M. Boonen ... [et al.] -- - Impact of pharmaceutical regulation and policies on health system performance goals in israel - Philip Sax and Amir Shmueli -- - Global budgets and provider incentives : hospitals' drug expenditures in Taiwan - Shin-Yi Chou ... [et al.] -- - Medicare Part D turns four : trends in plan design, enrollment, and the impact of the program on beneficiaries - Jack Hoadley and Kosali Simon -- - Part III: U.S. studies : from markets to policy innovations -- - Does prescription drug adherence reduce hospitalizations and costs? The case of diabetes - William E. Encinosa, Didem Bernard and Avi Dor -- - Cost shring, benefit design, and adherence : the case of multiple sclerosis - Avi Dor ... [et al.] -- - Generic utilization and cost-sharing for prescription drugs - Teresa Bernard Gibson, Catherine G. McLaughlin and Dean G. Smith -- - Drug prices, out-of-pocket payments, and insurer costs : how do payers vary? - Jie Chen and John A. Rizzo -- - Adverse selection and the effect of health insurance on utilization of prescribed medicine among patients with chronic conditions - Yuriy Pylypchuk -- - The effect of drug vintage on survival : micro evidence from Puerto Rico's Medicaid program - Frank R. Lichtenberg -- - Part IV: Special topics -- - Retail pharmacy market structure and insurer-independent pharmacy bargaining in the Medicare Part D era - Yang Xie ... [et al.] -- - Patents, innovation, and the welfare effects of Medicare Part D - Adam Gailey, Darius Lakdawalla and Neeraj Sood The fields of pharmaceutical economics and health economics/policy are reaching a point of convergence. This is due to both the widespread availability of pharmaceutical treatments, accompanied by broader insurance coverage, and the regulation of prescription drugs in both private and government plans. This book will bridge the gap. We will explore developments in both U.S. and International setting. The system of the U.S. is characterized by a mix of private and government insurance for prescription drugs with the expansion of Medicare Part D. Most other developed countries are characterized by social insurance with either the government as a single payer such as in Canada or Australia, or a national health service as in many other European countries BUSINESS & ECONOMICS / Industries / Service bisacsh Health insurance / Costs fast Health insurance / Finance fast Medical economics fast Pharmaceutical industry / Economic aspects fast Drug Industry / economics Economics, Medical Insurance, Health / economics Gestion d'entreprises eclas Industrie Wirtschaft Pharmaceutical industry Economic aspects Medical economics Health insurance Finance Health insurance Costs Dor, Avi Sonstige oth Erscheint auch als Druck-Ausgabe, Hardcover 1-84950-716-3 Erscheint auch als Druck-Ausgabe, Hardcover 978-1-84950-716-5 http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=318261 Aggregator Volltext |
| spellingShingle | Pharmaceutical markets and insurance worldwide BUSINESS & ECONOMICS / Industries / Service bisacsh Health insurance / Costs fast Health insurance / Finance fast Medical economics fast Pharmaceutical industry / Economic aspects fast Drug Industry / economics Economics, Medical Insurance, Health / economics Gestion d'entreprises eclas Industrie Wirtschaft Pharmaceutical industry Economic aspects Medical economics Health insurance Finance Health insurance Costs |
| title | Pharmaceutical markets and insurance worldwide |
| title_auth | Pharmaceutical markets and insurance worldwide |
| title_exact_search | Pharmaceutical markets and insurance worldwide |
| title_full | Pharmaceutical markets and insurance worldwide edited by Avi Dor |
| title_fullStr | Pharmaceutical markets and insurance worldwide edited by Avi Dor |
| title_full_unstemmed | Pharmaceutical markets and insurance worldwide edited by Avi Dor |
| title_short | Pharmaceutical markets and insurance worldwide |
| title_sort | pharmaceutical markets and insurance worldwide |
| topic | BUSINESS & ECONOMICS / Industries / Service bisacsh Health insurance / Costs fast Health insurance / Finance fast Medical economics fast Pharmaceutical industry / Economic aspects fast Drug Industry / economics Economics, Medical Insurance, Health / economics Gestion d'entreprises eclas Industrie Wirtschaft Pharmaceutical industry Economic aspects Medical economics Health insurance Finance Health insurance Costs |
| topic_facet | BUSINESS & ECONOMICS / Industries / Service Health insurance / Costs Health insurance / Finance Medical economics Pharmaceutical industry / Economic aspects Drug Industry / economics Economics, Medical Insurance, Health / economics Gestion d'entreprises Industrie Wirtschaft Pharmaceutical industry Economic aspects Health insurance Finance Health insurance Costs |
| url | http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=318261 |
| work_keys_str_mv | AT doravi pharmaceuticalmarketsandinsuranceworldwide |